Advertisement
Screener

ANIXA BIOSCIENCES, INC. (ANIX) Proceeds from Convertible Debt

2.8 / 5 stars · 68/120 Roast Me

ANIXA BIOSCIENCES, INC. Proceeds from Convertible Debt

ANIXA BIOSCIENCES, INC. (ANIX) reported Proceeds from Convertible Debt of $3.50 million for the 12-month period ending 2014-10-31, per its 10-K filed 2015-12-23.

Discontinued › Cash Flow › Financing Activities

us-gaap:ProceedsFromConvertibleDebt · last filed 2015-12-23

  • ANIXA BIOSCIENCES, INC. proceeds from convertible debt for the quarter ending 2014-10-31 was $0.00.
  • ANIXA BIOSCIENCES, INC. proceeds from convertible debt for the quarter ending 2014-07-31 was $0.00.
  • ANIXA BIOSCIENCES, INC. proceeds from convertible debt for the quarter ending 2014-04-30 was $0.00.
  • ANIXA BIOSCIENCES, INC. proceeds from convertible debt for the quarter ending 2014-01-31 was $3.50M, a 98.30% increase year-over-year.
  • ANIXA BIOSCIENCES, INC. proceeds from convertible debt for fiscal 2014 was $3.50M, a 98.30% increase from fiscal 2013.
  • ANIXA BIOSCIENCES, INC. proceeds from convertible debt for fiscal 2013 was $1.76M, a 135.33% increase from fiscal 2012.
  • ANIXA BIOSCIENCES, INC. proceeds from convertible debt for fiscal 2012 was $750.00K.
Period endProceeds from Convertible Debt 3 monthProceeds from Convertible Debt 6 monthProceeds from Convertible Debt 9 monthProceeds from Convertible Debt 12 month
2014-10-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-23
$0.00
derived: sum of 2 quarters · filed 2015-12-23
$0.00
derived: sum of 3 quarters · filed 2015-12-23
$3.50M
10-K · filed 2015-12-23
2014-07-31$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-08-18
$0.00
derived: sum of 2 quarters · filed 2015-08-18
$3.50M
10-Q · filed 2015-08-18
$3.50M
derived: sum of 4 quarters · filed 2015-08-18
2014-04-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-05-22
$3.50M
10-Q · filed 2015-05-22
$3.50M
derived: sum of 3 quarters · filed 2015-05-22
$3.50M
derived: sum of 4 quarters · filed 2015-05-22
2014-01-31$3.50M
10-Q · filed 2015-03-09
$3.50M
derived: sum of 2 quarters · filed 2015-03-09
$3.50M
derived: sum of 3 quarters · filed 2015-03-09
$3.50M
derived: sum of 4 quarters · filed 2015-03-09
2013-10-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2015-01-29
$0.00
derived: sum of 2 quarters · filed 2015-01-29
$0.00
derived: sum of 3 quarters · filed 2015-01-29
$1.76M
10-K · filed 2015-01-29
2013-07-31$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-09-15
$0.00
derived: sum of 2 quarters · filed 2014-09-15
$1.76M
10-Q · filed 2014-09-15
2013-04-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-06-16
$1.76M
10-Q · filed 2014-06-16
2013-01-31$1.76M
10-Q · filed 2014-03-17
2012-10-31$750.00K
10-K/A · filed 2014-01-17

Similar stocks

Stock NameCountryMarket CapPE Ratio
CITIUS ONCOLOGY, INC. (CTOR)United States$0.097B-1.49
Milestone Pharmaceuticals Inc. (MIST)$0.098B-2.00
Acrivon Therapeutics, Inc. (ACRV)United States$0.091B-1.03
ProMIS Neurosciences Inc. (PMN)$0.102B
Rallybio Corp (RLYB)United States$0.089B
Polaryx Therapeutics, Inc. (PLYX)United States$0.106B
ONCOLYTICS BIOTECH INC (ONCY)$0.086B
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)United States$0.086B
Biomea Fusion, Inc. (BMEA)United States$0.107B-3.30
Lexaria Bioscience Corp. (LEXX)$0.084B-1.92